The Daiichi Sankyo CDK8 kinase inhibitor, DS96432529, is intended to be a bone anabolic agent. The molecule shows preclinical efficacy and synergy with alendronate or parathyroid hormone. The discovery program was initiated well before the likely target (CDK8) was identified and provides an interesting retrospective case study for [...]